{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:44:08Z","timestamp":1786157048048,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With life expectancies of patients with chronic myeloid leukemia (CML) now approaching those of the general population under tyrosine kinase inhibitor (TKI) therapy, understanding long-term treatment-related toxicities becomes paramount. Although imatinib\u2019s nephrotoxic potential is established, the renal safety profiles of second-generation TKIs\u2014dasatinib, nilotinib, and flumatinib\u2014remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study analyzed renal function trajectories in 348 patients with CML receiving first-line imatinib, dasatinib, nilotinib, or flumatinib. Renal function was assessed using serum creatinine and estimated glomerular filtration rate (eGFR). Mixed-effects models incorporating treatment group, time, and their interaction as fixed effects were used to formally compare eGFR trajectories across treatment groups. Chronic renal adverse events and acute kidney injury were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Formal comparison of eGFR trajectories across treatment groups revealed a significant time \u00d7 treatment interaction, indicating differential renal function changes among the 4 TKIs. Significant serum creatinine elevation and eGFR decline were observed in imatinib and flumatinib groups, contrasting with stable creatinine and divergent eGFR patterns in dasatinib (slight increase) and nilotinib (decline) groups. The incidence of chronic renal adverse events varied substantially across cohorts\u201412.3% (imatinib), 2.6% (nilotinib), 4.3% (dasatinib), and 9.6% (flumatinib). Notably, among 3 documented acute kidney injury cases, all occurred during flumatinib treatment. Furthermore, treatment-free remission achievement did not confer significant renal function recovery, suggesting potential irreversibility of established renal damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TKIs exhibit differential renal safety profiles, underscoring the critical importance of individualized TKI selection based on baseline renal status and implementation of rigorous renal monitoring protocols throughout treatment duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag283","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:40:15Z","timestamp":1784374815000},"source":"Crossref","is-referenced-by-count":0,"title":["Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis"],"prefix":"10.1093","volume":"31","author":[{"given":"Sanmei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2101-0489","authenticated-orcid":false,"given":"Chun","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-1243","authenticated-orcid":false,"given":"Ming","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixuan","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-4027","authenticated-orcid":false,"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026080722165401800_oyag283-B1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/1078155217710553","article-title":"BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"24","author":"Cuellar","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2026080722165401800_oyag283-B2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080722165401800_oyag283-B3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2026080722165401800_oyag283-B4","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080722165401800_oyag283-B5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080722165401800_oyag283-B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multi-center FESTnd study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026080722165401800_oyag283-B7","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","article-title":"Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients","volume":"22","author":"Marcolino","year":"2011","journal-title":"Ann Oncol"},{"key":"2026080722165401800_oyag283-B8","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","article-title":"Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"121","author":"Yilmaz","year":"2015","journal-title":"Cancer"},{"key":"2026080722165401800_oyag283-B9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12185-016-2071-6","article-title":"Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia","volume":"104","author":"Hino","year":"2016","journal-title":"Int J Hematol"},{"key":"2026080722165401800_oyag283-B10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.leukres.2008.07.029","article-title":"Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia","volume":"33","author":"Holstein","year":"2009","journal-title":"Leuk Res"},{"key":"2026080722165401800_oyag283-B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/08860220903391226","article-title":"Acute renal failure under dasatinib therapy","volume":"32","author":"Ozkurt","year":"2010","journal-title":"Ren Fail"},{"key":"2026080722165401800_oyag283-B12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026080722165401800_oyag283-B13","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2026080722165401800_oyag283-B14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1)","volume":"17","author":"Kellum","year":"2013","journal-title":"Crit Care"},{"key":"2026080722165401800_oyag283-B15","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"2026080722165401800_oyag283-B16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"2026080722165401800_oyag283-B17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00277-019-03690-2","article-title":"Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors","volume":"98","author":"Ren","year":"2019","journal-title":"Ann Hematol"},{"key":"2026080722165401800_oyag283-B18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/ajh.23125","article-title":"Pharmacokinetics of nilotinib in imatinib-resistant\/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure","volume":"87","author":"Onaka","year":"2012","journal-title":"Am J Hematol"},{"key":"2026080722165401800_oyag283-B19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2215\/CJN.0000000000000219","article-title":"Patient-specific pharmacokinetics and dasatinib nephrotoxicity","volume":"18","author":"Adegbite","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026080722165401800_oyag283-B20","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag283\/69682592\/oyag283.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag283\/69682592\/oyag283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag283\/69682592\/oyag283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:16:59Z","timestamp":1786155419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag283\/8739087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag283","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,21]]},"article-number":"oyag283"}}